CN101069710A - Compounded medicine for preventing and treating metabolic syndrome and hyperlimemia - Google Patents
Compounded medicine for preventing and treating metabolic syndrome and hyperlimemia Download PDFInfo
- Publication number
- CN101069710A CN101069710A CNA2006100800680A CN200610080068A CN101069710A CN 101069710 A CN101069710 A CN 101069710A CN A2006100800680 A CNA2006100800680 A CN A2006100800680A CN 200610080068 A CN200610080068 A CN 200610080068A CN 101069710 A CN101069710 A CN 101069710A
- Authority
- CN
- China
- Prior art keywords
- herb gynostemmae
- gynostemmae pentaphylli
- group
- total glycosides
- total flavones
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a compound Chinese medicine for preventing and curing metabolic syndrome or hyperlipemia. It is characterized by that said compound Chinese medicine is made up by using car taegus fruit total flavone, gynostemma pentaphyllum total glycoside and proper quantity of pharmaceutical accepdable carrier through a certain preparation process. Besides, said compound Chinese medicine also can be used for preventing and curing the diseases of atherosclerosis and fatty liver, etc.
Description
Technical field
The present invention relates to a kind of compound medicines that is used to prevent and treat metabolism syndrome or hyperlipemia, and the purposes of this compound medicines in the preparation medicine.Belong to pharmaceutical field.
Background technology
Epidemiological study finds that many people exist hypertension, central obesity, blood fat disorder and hyperglycemia simultaneously, and it is very high that cardiovascular disease risk takes place these people.Reaven was referred to as " X syndrome " to a plurality of metabolic diseases of this kind simultaneous situation in a human body in 1988, and multiple titles such as " insulin resistance syndromes " is arranged again later on.The World Health Organization's suggestion employing " metabolism syndrome " in 1999 (metabolic syndrome, MS).MS is the presentation of one group of complicated symptom combination, and these symptoms comprise obesity, dyslipidemia, insulin resistant, hypertension, type 2 diabetes mellitus etc.Disclosedly in the patent documentation be used to prepare the medicine for the treatment of metabolism syndrome and have: the disclosed Chinese medicine pharmaceutical composition of CN patent 03133889 application; CN patent 00127877 disclosed steroid dehydrogenase; PCT patent 02820658 disclosed estradiol metabolites; PCT patent 01814761 disclosed a kind of pyrazole derivatives; PCT patent 01813397 disclosed imdazole derivatives; PCT patent 01821884 disclosed lactobacillus strains is Lactobacillus plantarum 299 (DSM6595) or Lactobacillus plantarum 299v (DSM9843) especially; The PCT patent 01803904 disclosed compositions that is used to transmit contisol antagonist.Though have above-mentioned many treatment metabolism syndrome medicines, in clinical effective application, remain in very big distance.
Hyperlipemia is the important risk factor of cardiovascular and cerebrovascular disease, can be a kind of presentation of metabolism syndrome, also usually as a kind of disease individualism.Wherein, when serum total cholesterol (TC) and the total triglyceride of serum (TG) when raising simultaneously, be called combined hyperlipidemia, the combined hyperlipidemia patient accounts for total hyperlipemia patient's 40%.As the common type of combined hyperlipidemia, the prevalence of familial combined hyperlipidemiam in general crowd is 0.5～2.0%, is 3 times of familial hypercholesterolemia prevalence.Helsinki cardiac studies finds that familial combined hyperlipidemiam patient dyslipidemia individuality is than low-density lipoprotein cholesterol (LDL-c) or the TG easier generation that causes coronary heart disease of individuality of rising separately.The sickness rate of its hypertension of familial combined hyperlipidemiam patient, obesity and diabetes increases.
At present, the chemicals of Chang Yong blood lipid regulation is the special class of HMG-CoA reductase inhibitor (Statins) and shellfish clinically, and his spit of fland is mainly used in the reduction cholesterolemia, and the special class of shellfish is mainly used in triglyceride reducing.For the combined hyperlipidemia patient that TC and TG raise simultaneously, with Statins and the special class coupling of shellfish, possible benefit is solely taken greater than two prescriptions.But American National cholesterol education project adult treats group meeting III and advises the careful this therapeutic alliance of using, because of the possibility that increases rhabdomyolysis danger is arranged.
The Graham of U.S. FDA etc. have carried out the rhabdomyolysis assessment of risks to the patient who accepts the treatment of Statins and/or fibrate lipid-lowering medicine during 1998～calendar year 2001.The result shows, accepts among the patient of lipid lowerers treatment in 252 460 example while in hospitals, and rhabdomyolysis has taken place 24 examples; The rhabdomyolysis incidence rate is all 0.44/ ten thousand man-year due to atorvastatin, pravastatin or the simvastatin single therapy, and cerivastatin is 5.34/ ten thousand man-year, and the special class of shellfish is 2.82/ ten thousand man-year; When atorvastatin, pravastatin or simvastatin and the coupling of shellfish spy class, the rhabdomyolysis incidence rate can increase to 5.98/ ten thousand man-year, the special class coupling of cerivastatin and shellfish then increases to 1035/ ten thousand man-year [Graham DJ, Staffa JA, Shatin D, et al.Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.JAMA，2004，92(21)：2585]。The anticholesteremic agent of Beyer Co., Ltd is visitd sthene (cerivastatin) in listing in 1997, enters Chinese market in 1999.From visiing after sthene pushes market, U.S. FDA receives that 31 examples cause that because of visiing sthene rhabdomyolysis causes dead report, wherein the patient unites and has used gemfibrozil (lipid lowerers of the special class of a kind of shellfish), Beyer Co., Ltd to be forced to that initiatively will visit sthene withdraws from market in 12 reports.Recently studies show that glucuronidation is the important channel that Statins is removed, and the special class of shellfish can suppress his spit of fland glucuronidation effect, this may be that the special class of shellfish can increase the weight of the reason that Statins causes myopathy danger.
But for the treatment of combined hyperlipidemia, except that said medicine, still do not have other active drug at present, more do not have the patient and take more convenient compound medicine.General still suggestion is share in TC and TG Ta Ting and Bei Te all high and use the refractory patient that his spit of fland or fibrate can not disease controlling separately under the situation of tight monitoring.
Put into practice for many years and studies show that, China's tradition Chinese medicine has special advantages aspect treatment hyperlipemia and the complication thereof, some traditional herbal medicines can be from regulating lipid metabolism, suppress lipid peroxidation, improve hemorheology, suppress aspect such as smooth muscle cell proliferation, and multipath, too many levels, many target spots exert an influence to disease.
Chinese medicine worker centering medicine single medicinal material is prevented and treated hyperlipemia and is screened in recent years, finds that many Chinese medicines have effect for reducing blood fat.Can on determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, select medication clinically, will be of great advantage to the treatment of primary disease.As select Fructus Crataegi, the Radix Polygoni Multiflori, Fructus Lycii, the Cortex Eucommiae, Folium Ginkgo, Herba Taxilli, Radix Puerariae, Radix Glycyrrhizae for use based on cholesterol reducing; Flos Lonicerae, Fructus Ilicis Purpureae based on triglyceride reducing; To all effective Herb Gynostemmae Pentaphylli of cholesterol, triglyceride, Radix Ginseng, Fructus Ligustri Lucidi, Herba Artemisiae Scopariae, Rhizoma Polygoni Cuspidati, Pollen Typhae, Semen Cassiae, Cordyceps, Rhizoma Alismatis, pollen, Rhizoma Polygonati, Semen phaseoli radiati etc.
In single medicinal material, Fructus Crataegi and Herb Gynostemmae Pentaphylli are the most commonly used.The Fructus Crataegi beginning is stated from " Amplification on Materia Medica addendum ", is the dry mature fruit of rosaceous plant Fructus Pyri Pashiae (Crataegus pinnatifida Bge.Var.major N.E.Br) or Fructus Crataegi (Crataegus pinnatifida Bge.).Its sour in the mouth is sweet, and slightly warm in nature is returned spleen, stomach, Liver Channel, and motherland's medical science thinks that crataegus pin natifida var. Major has stagnant, the functions such as spleen reinforcing is good for the stomach, blood circulation promoting and blood stasis dispelling of removing food stagnancyization.And organic acid and flavone compound that modern studying data at home and abroad proof Fructus Crataegi contains have more many-sided pharmacological action, and be especially comparatively remarkable for the effect of digestive system, lipid metabolism and cardiovascular system.Experimentation shows that the different extract parts of Fructus Crataegi all have sure effect for reducing fat to the various high blood lipid models that different animals causes.
(Gynostemma pentaphyllum Gyp) is the herbaceous species plant of Cucurbitaceae Gynostemma to Herb Gynostemmae Pentaphylli, and the beginning is stated from Ming Dynasty's herbal for Relief of Famines, has another name called Pentapanax, gynostemma pentaphyllum makino, Herba Gynostemmatis etc.Its bitter in the mouth is cold in nature, has the spleen invigorating of nourishing heart, QI invigorating and blood regulating, the merit of expectorant blood stasis dispelling.Herb Gynostemmae Pentaphylli total glycosides (Gypenosides, GP) be isolated total glycosides from gynostemma plant, including has 6 kinds of tetracyclic triterpene dammarane type structures with the ginsenoside identical in 84 kinds of saponin, all the other are ginsenoside's isomer, so be called as " southern Radix Ginseng ".Modern study shows that GP has effects such as anti-arteriosclerosis, antithrombotic formation, blood pressure regulation, blood fat reducing.It can reduce blood cholesterol, triglyceride, low density lipoprotein, LDL, high density lipoprotein increasing, suppresses arterial wall and the lipidosis of liver and the increase of lipid peroxide concentration, obvious SOD activity improving, thus adjust lipid metabolic disorder.
Chinese medicine compound such as Chinese traditional medicines depressing lipid are made up of Radix Pseudostellariae, the Radix Polygoni Multiflori, Rhizoma Curcumae Longae, Pollen Tyjphae, living Folium Nelumbinis, Rhizoma Alismatis etc.; The yellow tablets of reducing blood fat of cowherb is made up of medicines such as Rhizoma Curcumae Longae, Rhizoma Curcumae, Rhizoma Polygonati, Rhizoma Polygonati Odorati, Radix Et Rhizoma Rhei, Fructus Crataegi, Rhizoma Acori Graminei, Radix Bupleuri; Function of gallbladder promoting the liver benefiting soup is made up of Fructus Ligustri Lucidi, the Radix Polygoni Multiflori, Rhizoma Polygoni Cuspidati, Herba Artemisiae Scopariae, Rhizoma Alismatis, Radix Salviae Miltiorrhizae, Fructus Crataegi etc.; Fat can be square clearly, is made up of Semen Lepidii (Semen Descurainiae), Radix Scutellariae, Herba Artemisiae Scopariae, Fructus Crataegi, Rhizoma Alismatis, Radix Et Rhizoma Rhei, the Radix Aucklandiae; Transfer fat soup, form, better curative effect is all arranged through clinical verification treatment hyperlipemia by Radix Glycyrrhizae, Fructus Lycii, Rhizoma Alismatis, Radix Bupleuri, Fructus Crataegi, Radix Salviae Miltiorrhizae, Flos Carthami.
The Chinese medicine compound flavour of a drug are many, and every flavor Chinese medicine contains multiple composition again, so wayward at aspects such as pharmacodynamic analysis and quality inspections.Along with the development of society, the quickening of rhythm of life, the fried of Chinese medicine compound brought inconvenience with carrying also to the patient.Therefore, exploitation effectively, low toxicity, compound medicines easily, be the treatment field problem demanding prompt solution of metabolism syndrome and combined hyperlipidemia.
Summary of the invention
The invention provides a kind of determined curative effect, safe ready, the little pure traditional Chinese compound medicine of side effect, the present invention also provides the purposes of this compound medicines in the medicine of preparation prevention or treatment metabolism syndrome or hyperlipemia.
Prescription is formed: a kind of Chinese medicine compound provided by the invention, make by the Chinese medicine extract of following weight proportion: Fructus Crataegi total flavones, Herb Gynostemmae Pentaphylli total glycosides, and pharmaceutics on acceptable carrier an amount of; Wherein the weight proportion of Fructus Crataegi total flavones and Herb Gynostemmae Pentaphylli total glycosides is 1: 4～4: 1; Fructus Crataegi total flavones is total flavones that extracts or the total flavones that extracts from Folium Crataegi from Fructus Crataegi.
Preferred 1: 2～2: 1 of the weight proportion of above-mentioned Fructus Crataegi total flavones and Herb Gynostemmae Pentaphylli total glycosides; Be more preferably 1: 1.
A kind of Chinese medicine compound provided by the invention, make by the Chinese medicine extract of following weight proportion: Fructus Crataegi total flavones 30～120mg, Herb Gynostemmae Pentaphylli total glycosides 120～30mg, and pharmaceutics on acceptable carrier an amount of; Fructus Crataegi total flavones is total flavones that extracts or the total flavones that extracts from Folium Crataegi from Fructus Crataegi.
Wherein preferably make by the Chinese medicine extract of following weight proportion: Fructus Crataegi total flavones 30～60mg, Herb Gynostemmae Pentaphylli total glycosides 60～30mg, and pharmaceutics on acceptable carrier an amount of.
Be more preferably by the Chinese medicine extract of following weight proportion and make: Fructus Crataegi total flavones 60mg, Herb Gynostemmae Pentaphylli total glycosides 60mg, and pharmaceutics on acceptable carrier an amount of.
The Fructus Crataegi total flavones that the invention provides in the compound medicines comprises total flavones that extracts or the total flavones that extracts from Folium Crataegi from Fructus Crataegi, comprise hyperin (hyperoside) particularly, vitexin rhamnoside (vitexin rhamnoside) (promptly 5,7,4 '-trihydroxyflavone-8-C-α-L-rhamnopyranosyl-(1 → 2)-β-D-pyranglucoside), citric acid (citric acid), vitexin (vitexin), Quercetin (quercetin), ursolic acid (ursolic acid) etc.
Fructus Crataegi extract of the present invention (total flavones): by the prepared under " Fructus Crataegi extract quality standard " item under " Chinese traditional patent formulation preparation " the 9th " SHANZHAJING JIANGZHI PIAN " item, promptly.
Assay: the content assaying method by under " Fructus Crataegi extract quality standard " item in dry product, contains total flavones with anhydrous Quercetin (C
15H
10O
7) calculate, must not be less than 8.0%.
Folium Crataegi total flavones of the present invention: by " prepared under " Folium Crataegi extract " item under " Yixintong sheet " item of Chinese pharmacopoeia version in 2005, promptly.
Assay: the content assaying method by under " Folium Crataegi extract " item in dry product, contains total flavones with anhydrous rutin (C
27H
30O
16) meter, must not be less than 80.0%; Contain hyperin (C
21H
20O
12), must not be less than 0.40%.
Herb Gynostemmae Pentaphylli total glycosides in the compound medicines provided by the invention comprises: GynosaponinTN-1, Gypenoside LXX VII, Gypenoside XL VI, Gynsenoside Rd and 3-O-β-D-glucopyranosyl 2 α, 3 β, kind of panoxadiol's type triterpene saponin surplus 12 β, 20 (S)-3 hydroxyls-dammarane 24-alkene 20-O-β-D-pyranglucoside etc. 80.
Herb Gynostemmae Pentaphylli total glycosides of the present invention: press Zhao Zhengsheng (Zhao Zhengsheng, Ren Hongfeng. Herb Gynostemmae Pentaphylli total glycosides Study on extraction and improvement, Chinese herbal medicine, 1995,26 (11): 580～581) extracting method of Herb Gynostemmae Pentaphylli total glycosides extracts in accordance with the law, promptly.
Assay: measure by " new drug become a full member standard " the 4th " Herb Gynostemmae Pentaphylli total glycosides " content assaying method down, press dry product calculating, contain total glycosides with gypenoside-A (C
53H
90O
21) meter, must not be less than 70.0%.
The preparation method of this compound preparation may further comprise the steps:
A. get acceptable carrier crushing screening on Fructus Crataegi total flavones, Herb Gynostemmae Pentaphylli total glycosides and an amount of pharmaceutics, mix homogeneously;
B. make soft material with The suitable solvent, granulate, drying, to water content be about 3%;
C. take out, granulate with moderate lubrication agent mix homogeneously, is pressed into or is filled to preparation according to a conventional method.
Pharmaceutics acceptable carrier in this compound medicines, include the excipient and the accessory drugs that help reactive compound is mixed with pharmaceutical formulation, compositions as one or more materials of starch, microcrystalline Cellulose, inorganic salts, sucrose, dextrin, lactose, Icing Sugar, glucose, sodium chloride, cysteine, citric acid and sodium sulfite etc. belongs to this area general knowledge.This compound medicines can be made into ordinary tablet, oral cavity quick disintegrating slice, dispersible tablet, double-layer tablet, multilayer tablet, slow releasing tablet, single chamber controlled release tablet, two chambers controlled release tablet, pore type controlled release tablet, sublingual lozenge, enteric coatel tablets, granule, pill, enteric coated capsule, delayed-release tablet, regularly/position releasing piece, conventional capsule, soft capsule, slow releasing capsule, controlled release capsule, sustained-release micro-spheres, contain micropill or small pieces capsule, contain the dosage forms such as pH dependent form capsule, granule, oral liquid, membrane or patch of micropill or small pieces.
Preparation of the present invention is determined usage and dosage according to patient's practical situation, can take every day three times, perhaps takes once every day with slow release or controlled release mode.
Beneficial effect of the present invention:
(1) compound medicines provided by the invention has significant collaborative effect for reducing fat to the hyperlipidemia rat;
(2) compound medicines provided by the invention is fed to high lipid food and is caused that atherosclerotic rabbit has significant The synergistic anti-atherosclerotic effect;
(3) compound medicines provided by the invention has the effect of significant collaborative control fatty liver;
(4) compound medicines provided by the invention has the effect of significant collaborative control metabolism syndrome;
(5) compound medicines provided by the invention need not decoction, taking convenience, no bitterness sense, and side effect is little, and expense is low, and patient's compliance is good.
The specific embodiment
Below the present invention will be further described by specific embodiment.
Embodiment 1 Fructus Crataegi extract (total flavones) 60mg+ Herb Gynostemmae Pentaphylli total glycosides 60mg preparation
The present invention is that Fructus Crataegi extract 60mg, Herb Gynostemmae Pentaphylli total glycosides 60mg compositions comprise pharmaceutically acceptable preparation.
(1) tablet: get Fructus Crataegi extract 60g, Herb Gynostemmae Pentaphylli total glycosides 60g, microcrystalline Cellulose 40g, starch 40g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, and mix homogeneously is pressed into 1000, the bag film-coat, promptly.This product contains total flavones with anhydrous Quercetin (C
15H
10O
7) calculate, every must not be less than 4.5mg, contains total glycosides with gypenoside-A (C
53H
90O
21) meter, should be 90～110% of labelled amount.
(2) capsule: get Fructus Crataegi extract 60g, Herb Gynostemmae Pentaphylli total glycosides 60g, microcrystalline Cellulose 40g, starch 40g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, incapsulates, and makes 1000, promptly.。This product contains total flavones with anhydrous Quercetin (C
15H
10O
7) calculate, every must not be less than 4.5mg, contains total glycosides with gypenoside-A (C
53H
90O
21) meter, should be 90～110% of labelled amount.
(3) granule: get Fructus Crataegi extract 30g, Herb Gynostemmae Pentaphylli total glycosides 30g, dextrin 300g, cane sugar powder 640g, mix homogeneously adds 70% ethanol and makes granule in right amount, makes 1000g, packing, and every packed 2g, promptly.This product contains total flavones with anhydrous Quercetin (C
15H
10O
7) calculate, every bag must not be less than 4.5mg, contains total glycosides with gypenoside-A (C
53H
90O
21) meter, should be 90～110% of labelled amount.
(4) soft capsule: get Fructus Crataegi extract 60g, Herb Gynostemmae Pentaphylli total glycosides 60g, soybean salad oil 280g, Cera Flava 3g, soybean salad oil is heated to about 85 ℃, add Cera Flava and make fusing, stir and make mix homogeneously; When treating that temperature is reduced to 25～35 ℃, micronized Fructus Crataegi extract, Herb Gynostemmae Pentaphylli total glycosides are added in the mixed solution, stir to make and reduce to room temperature, cross colloid mill, placement makes the degassing, rotating mould platen press be pressed into 1000, promptly.This product contains total flavones with anhydrous Quercetin (C
15H
10O
7) calculate, every must not be less than 4.5mg, contains total glycosides with gypenoside-A (C
53H
90O
21) meter, should be 90～110% of labelled amount.
Embodiment 2 Fructus Crataegi extracts (total flavones) 30mg+ Herb Gynostemmae Pentaphylli total glycosides 60mg preparation
The present invention is that Fructus Crataegi extract 30mg, Herb Gynostemmae Pentaphylli total glycosides 60mg compositions comprise pharmaceutically acceptable preparation.
(1) tablet: get Fructus Crataegi extract 30g, Herb Gynostemmae Pentaphylli total glycosides 60g, microcrystalline Cellulose 55g, starch 55g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, and mix homogeneously is pressed into 1000, the bag film-coat, promptly.
(2) capsule: get Fructus Crataegi extract 30g, Herb Gynostemmae Pentaphylli total glycosides 60g, microcrystalline Cellulose 55g, starch 55g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, incapsulates, and makes 1000, promptly.
(3) granule: get Fructus Crataegi extract 15g, Herb Gynostemmae Pentaphylli total glycosides 30g, dextrin 300g, sucrose 655g, mix homogeneously adds 70% ethanol and makes granule in right amount, makes 1000g, packing, and every packed 2g, promptly.
(4) soft capsule: get Fructus Crataegi extract 30g, Herb Gynostemmae Pentaphylli total glycosides 60g, soybean salad oil 210g, Cera Flava 3g, soybean salad oil is heated to about 85 ℃, add Cera Flava and make fusing, stir and make mix homogeneously; When treating that temperature is reduced to 25～35 ℃, micronized Fructus Crataegi extract, Herb Gynostemmae Pentaphylli total glycosides are added in the mixed solution, stir to make and reduce to room temperature, cross colloid mill, placement makes the degassing, rotating mould platen press be pressed into 1000, promptly.
Embodiment 3 Fructus Crataegi extracts (total flavones) 60mg+ Herb Gynostemmae Pentaphylli total glycosides 30mg preparation
The present invention is that Fructus Crataegi extract 60mg, Herb Gynostemmae Pentaphylli total glycosides 30mg compositions comprise pharmaceutically acceptable preparation.
(1) tablet: get Fructus Crataegi extract 60g, Herb Gynostemmae Pentaphylli total glycosides 30g, microcrystalline Cellulose 55g, starch 55g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, and mix homogeneously is pressed into 1000, the bag film-coat, promptly.
(2) capsule: get Fructus Crataegi extract 60g, Herb Gynostemmae Pentaphylli total glycosides 30g, microcrystalline Cellulose 55g, starch 55g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, incapsulates, and makes 1000, promptly.
(3) granule: get Fructus Crataegi extract 30g, Herb Gynostemmae Pentaphylli total glycosides 15g, dextrin 300g, sucrose 655g, mix homogeneously adds 70% ethanol and makes granule in right amount, makes 1000g, packing, and every packed 2g, promptly.
(4) soft capsule: get Fructus Crataegi extract 60g, Herb Gynostemmae Pentaphylli total glycosides 30g, soybean salad oil 210g, Cera Flava 3g, soybean salad oil is heated to about 85 ℃, add Cera Flava and make fusing, stir and make mix homogeneously; When treating that temperature is reduced to 25～35 ℃, micronized Fructus Crataegi extract, Herb Gynostemmae Pentaphylli total glycosides are added in the mixed solution, stir to make and reduce to room temperature, cross colloid mill, placement makes the degassing, rotating mould platen press be pressed into 1000, promptly.
Embodiment 4 Fructus Crataegi extracts (total flavones) 30mg+ Herb Gynostemmae Pentaphylli total glycosides 30mg preparation
The present invention is that Fructus Crataegi extract 30mg, Herb Gynostemmae Pentaphylli total glycosides 30mg compositions comprise pharmaceutically acceptable preparation.
(1) tablet: get Fructus Crataegi extract 30g, Herb Gynostemmae Pentaphylli total glycosides 30g, microcrystalline Cellulose 70g, starch 70g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, and mix homogeneously is pressed into 1000, the bag film-coat, promptly.
(2) capsule: get Fructus Crataegi extract 30g, Herb Gynostemmae Pentaphylli total glycosides 30g, microcrystalline Cellulose 70g, starch 70g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, incapsulates, and makes 1000, promptly.
(3) granule: get Fructus Crataegi extract 15g, Herb Gynostemmae Pentaphylli total glycosides 15g, dextrin 300g, sucrose 670g, mix homogeneously adds 70% ethanol and makes granule in right amount, makes 1000g, packing, and every packed 2g, promptly.
(4) soft capsule: get Fructus Crataegi extract 30g, Herb Gynostemmae Pentaphylli total glycosides 30g, soybean salad oil 240g, Cera Flava 3g, soybean salad oil is heated to about 85 ℃, add Cera Flava and make fusing, stir and make mix homogeneously; When treating that temperature is reduced to 25～35 ℃, micronized Fructus Crataegi extract, Herb Gynostemmae Pentaphylli total glycosides are added in the mixed solution, stir to make and reduce to room temperature, cross colloid mill, placement makes the degassing, rotating mould platen press be pressed into 1000, promptly.
Embodiment 5 Folium Crataegi total flavones 30mg+ Herb Gynostemmae Pentaphylli total glycosides 60mg preparations
The present invention is that Folium Crataegi total flavones 30mg, Herb Gynostemmae Pentaphylli total glycosides 60mg compositions comprise pharmaceutically acceptable preparation.
(1) tablet: get Folium Crataegi total flavones 30g, Herb Gynostemmae Pentaphylli total glycosides 60g, microcrystalline Cellulose 70g, starch 40g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, and mix homogeneously is pressed into 1000, the bag film-coat, promptly.Every of this product contains hyperin (C
21H
20O
12), must not be less than 0.12mg, contain total glycosides with gypenoside-A (C
53H
90O
21) meter, should be 90～110% of labelled amount.
(2) capsule: get Folium Crataegi total flavones 30g, Herb Gynostemmae Pentaphylli total glycosides 60g, microcrystalline Cellulose 70g, starch 40g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, and mix homogeneously incapsulates, and makes 1000, promptly.Every of this product contains hyperin (C
21H
20O
12), must not be less than 0.12mg, contain total glycosides with gypenoside-A (C
53H
90O
21) meter, should be 90～110% of labelled amount.
(3) granule: get Folium Crataegi total flavones 15g, Herb Gynostemmae Pentaphylli total glycosides 30g, dextrin 400g, sucrose 555g, mix homogeneously adds 70% ethanol and makes granule in right amount, makes 1000g, packing, and every packed 2g, promptly.This product contains hyperin (C for every bag
21H
20O
12), must not be less than 0.12mg, contain total glycosides with gypenoside-A (C
53H
90O
21) meter, should be 90～110% of labelled amount.
(4) soft capsule: get Folium Crataegi total flavones 30g, Herb Gynostemmae Pentaphylli total glycosides 60g, soybean salad oil 207g, Cera Flava 3g, soybean salad oil is heated to about 85 ℃, add Cera Flava and make fusing, stir and make mix homogeneously; When treating that temperature is reduced to 25～35 ℃, micronized Folium Crataegi extract, Herb Gynostemmae Pentaphylli total glycosides are added in the mixed solution, stir to make and reduce to room temperature, cross colloid mill, placement makes the degassing, rotating mould platen press be pressed into 1000, promptly; Or Folium Crataegi total flavones 30g, Herb Gynostemmae Pentaphylli total glycosides 60g, liquid polyethylene glycol 180g, 10g Macrogol 4000, glycerol 20g, liquid polyethylene glycol is heated to about 90 ℃, add Macrogol 4000 and make fusing, treat to add glycerol when temperature is reduced to 40 ℃, stir and make mix homogeneously; When treating that temperature is reduced to 25～35 ℃, micronized Folium Crataegi extract, Herb Gynostemmae Pentaphylli total glycosides are added in the mixed solution, stir to make and reduce to room temperature, cross colloid mill, placement makes the degassing, rotating mould platen press be pressed into 1000, promptly.Every of this product contains hyperin (C
21H
20O
12), must not be less than 0.12mg, contain total glycosides with gypenoside-A (C
53H
90O
21) meter, should be 90～110% of labelled amount.
Embodiment 6 Folium Crataegi total flavones 60mg+ Herb Gynostemmae Pentaphylli total glycosides 30mg preparations
The present invention is that Folium Crataegi total flavones 60mg, Herb Gynostemmae Pentaphylli total glycosides 30mg compositions comprise pharmaceutically acceptable preparation.
(1) tablet: get Folium Crataegi total flavones 60g, Herb Gynostemmae Pentaphylli total glycosides 30g, microcrystalline Cellulose 70g, starch 40g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, and mix homogeneously is pressed into 1000, the bag film-coat, promptly.
(2) capsule: get Folium Crataegi total flavones 60g, Herb Gynostemmae Pentaphylli total glycosides 30g, microcrystalline Cellulose 70g, starch 40g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, and mix homogeneously incapsulates, and makes 1000, promptly.
(3) granule: get Folium Crataegi total flavones 30g, Herb Gynostemmae Pentaphylli total glycosides 15g, dextrin 300g, sucrose 655g, mix homogeneously adds 70% ethanol and makes granule in right amount, makes 1000g, packing, and every packed 2g, promptly.
(4) soft capsule: get Folium Crataegi total flavones 60g, Herb Gynostemmae Pentaphylli total glycosides 30g, soybean salad oil 207g, Cera Flava 3g, soybean salad oil is heated to about 85 ℃, add Cera Flava and make fusing, stir and make mix homogeneously; When treating that temperature is reduced to 25～35 ℃, micronized Folium Crataegi extract, Herb Gynostemmae Pentaphylli total glycosides are added in the mixed solution, stir to make and reduce to room temperature, cross colloid mill, placement makes the degassing, rotating mould platen press be pressed into 1000, promptly; Or Folium Crataegi total flavones 60g, Herb Gynostemmae Pentaphylli total glycosides 30g, liquid polyethylene glycol 180g, 10g Macrogol 4000, glycerol 20g, liquid polyethylene glycol is heated to about 90 ℃, add Macrogol 4000 and make fusing, treat to add glycerol when temperature is reduced to 40 ℃, stir and make mix homogeneously; When treating that temperature is reduced to 25～35 ℃, micronized Folium Crataegi extract, Herb Gynostemmae Pentaphylli total glycosides are added in the mixed solution, stir to make and reduce to room temperature, cross colloid mill, placement makes the degassing, rotating mould platen press be pressed into 1000, promptly.
Embodiment 7 Folium Crataegi total flavones 60mg+ Herb Gynostemmae Pentaphylli total glycosides 60mg preparations
The present invention is that Folium Crataegi total flavones 60mg, Herb Gynostemmae Pentaphylli total glycosides 60mg compositions comprise pharmaceutically acceptable preparation.
(1) tablet: get Folium Crataegi total flavones 60g, Herb Gynostemmae Pentaphylli total glycosides 60g, microcrystalline Cellulose 40g, starch 40g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, and mix homogeneously is pressed into 1000, the bag film-coat, promptly.
(2) capsule: get Folium Crataegi total flavones 60g, Herb Gynostemmae Pentaphylli total glycosides 60g, microcrystalline Cellulose 40g, starch 40g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, and mix homogeneously incapsulates, and makes 1000, promptly.
(3) granule: get Folium Crataegi total flavones 30g, Herb Gynostemmae Pentaphylli total glycosides 30g, dextrin 300g, sucrose 640g, mix homogeneously adds 70% ethanol and makes granule in right amount, makes 1000g, packing, and every packed 2g, promptly.
(4) soft capsule: get Folium Crataegi total flavones 60g, Herb Gynostemmae Pentaphylli total glycosides 60g, soybean salad oil 280g, Cera Flava 4g, soybean salad oil is heated to about 85 ℃, add Cera Flava and make fusing, stir and make mix homogeneously; When treating that temperature is reduced to 25～35 ℃, micronized Fructus Crataegi extract, Herb Gynostemmae Pentaphylli total glycosides are added in the mixed solution, stir to make and reduce to room temperature, cross colloid mill, placement makes the degassing, rotating mould platen press be pressed into 1000, promptly; Or Folium Crataegi total flavones 60g, Herb Gynostemmae Pentaphylli total glycosides 60g, liquid polyethylene glycol 240g, 20g Macrogol 4000, glycerol 20g, liquid polyethylene glycol is heated to about 90 ℃, add Macrogol 4000 and make fusing, treat to add glycerol when temperature is reduced to 40 ℃, stir and make mix homogeneously; When treating that temperature is reduced to 25～35 ℃, micronized Folium Crataegi extract, Herb Gynostemmae Pentaphylli total glycosides are added in the mixed solution, stir to make and reduce to room temperature, cross colloid mill, placement makes the degassing, rotating mould platen press be pressed into 1000, promptly.
Embodiment 8 Folium Crataegi total flavones 30mg+ Herb Gynostemmae Pentaphylli total glycosides 30mg preparations
The present invention is that Folium Crataegi total flavones 30mg, Herb Gynostemmae Pentaphylli total glycosides 30mg compositions comprise pharmaceutically acceptable preparation.
(1) tablet: get Folium Crataegi total flavones 30g, Herb Gynostemmae Pentaphylli total glycosides 30g, microcrystalline Cellulose 70g, starch 70g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, and mix homogeneously is pressed into 1000, the bag film-coat, promptly.
(2) capsule: get Folium Crataegi total flavones 30g, Herb Gynostemmae Pentaphylli total glycosides 30g, microcrystalline Cellulose 70g, starch 70g, mix homogeneously adds ethanol and makes granule in right amount, adds magnesium stearate 2g or micropowder silica gel 2g, and mix homogeneously incapsulates, and makes 1000, promptly.
(3) granule: get Folium Crataegi total flavones 15g, Herb Gynostemmae Pentaphylli total glycosides 15g, dextrin 300g, sucrose 670g, mix homogeneously adds 70% ethanol and makes granule in right amount, makes 1000g, packing, and every packed 2g, promptly.
(4) soft capsule: get Folium Crataegi total flavones 30g, Herb Gynostemmae Pentaphylli total glycosides 30g, soybean salad oil 237g, Cera Flava 3g, soybean salad oil is heated to about 85 ℃, add Cera Flava and make fusing, stir and make mix homogeneously; When treating that temperature is reduced to 25～35 ℃, micronized Folium Crataegi extract, Herb Gynostemmae Pentaphylli total glycosides are added in the mixed solution, stir to make and reduce to room temperature, cross colloid mill, placement makes the degassing, rotating mould platen press be pressed into 1000, promptly; Or Folium Crataegi total flavones 30g, Herb Gynostemmae Pentaphylli total glycosides 30g, liquid polyethylene glycol 210g, 10g Macrogol 4000, glycerol 20g, liquid polyethylene glycol is heated to about 90 ℃, add Macrogol 4000 and make fusing, treat to add glycerol when temperature is reduced to 40 ℃, stir and make mix homogeneously; When treating that temperature is reduced to 25～35 ℃, micronized Folium Crataegi extract, Herb Gynostemmae Pentaphylli total glycosides are added in the mixed solution, stir to make and reduce to room temperature, cross colloid mill, placement makes the degassing, rotating mould platen press be pressed into 1000, promptly.
Embodiment 9 Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones share the influence to the hyperlipemia rat blood fat
120 of male SD rats, adaptability was fed after 7 days, got 12 and was normal control group, feed normal diet; All the other rats high lipid food (prescription is: 7.5% Adeps Sus domestica, 0.8% cholesterol, 0.2% sodium cholate, 0.1% propylthiouracil, normal feedstuff 91.4%) of feeding is drunk 2% sucrose solution simultaneously.The 4th weekend, fasting was got hematometry Serum TC, TG after 12 hours, and the rat that serum TC, TG all significantly raise is a hyperlipidemia rats.
Hyperlipidemia rats is divided into model group, Herb Gynostemmae Pentaphylli total glycosides group (18mg/kg), Folium Crataegi total flavones group (18mg/kg), Herb Gynostemmae Pentaphylli total glycosides+Folium Crataegi total flavones low dose group (4.5+4.5mg/kg), middle dosage group (9+9mg/kg), high dose group (18+18mg/kg), 12 every group at random.Continue the high lipid food of feeding, gastric infusion, normal control group and model group give equivalent 0.5%CMC-Na solution, every day 2 times, in continuous 4 weeks, measure serum TC, TG, LDL, HDL the 4th weekend.
The result: compare with normal group, model group Serum TC, TG, LDL level significantly raise, and the HDL level reduces.Herb Gynostemmae Pentaphylli total glycosides group, Folium Crataegi total flavones group Serum TC, TG, LDL obviously reduce, and the HDL level raises, and has compared significant difference with model group; Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones share, Serum TC, TG, LDL further reduce, the HDL level further raises, and wherein middle dosage group effect is better than Herb Gynostemmae Pentaphylli total glycosides or Folium Crataegi total flavones list group, and has certain dose-effect relationship between the high, medium and low dosage group.
Show: the high lipid food of feeding can successfully duplicate the rat high blood lipid model, Herb Gynostemmae Pentaphylli total glycosides, Folium Crataegi total flavones gastric infusion, significantly improve the hyperlipidemia rats dyslipidemia, Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones share has significant synergism to blood lipid regulation.See Table 1.
Table 1 Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones are to the influence of hyperlipidemia rats blood fat
| Group | Dosage (mg/kg) | Number of animals | TC (mmol/L) | TG (mmol/L) | LDL (mmol/L) | HDL (mmol/L) |
| Normal group model group total glycosides total flavones total glycosides+total flavones | - - 18 18 4.5+4.5 9+9 18+18 | 11 10 11 9 10 11 12 | 1.49±0.32 10.6±2.57 ** 7.85±2.10 ▲▲ 8.12±1.66 ▲▲ 7.82±2.16 ▲▲ 6.06±1.72 ▲▲#※※ 5.96±1.12 ▲▲##※※ | 0.77±0.29 3.52±0.62 ** 2.80±0.58 ▲▲ 2.73±0.43 ▲▲ 3.26±0.74 2.34±0.32 ▲▲#※ 2.30±0.42 ▲▲#※ | 0.62±0.11 8.43±2.63 **6.70±1.38 ▲6.85±1.64 ▲6.44±1.97 ▲5.24±1.32 ▲▲#※4.92±1.11 ▲▲#※ | 1.28±0.23 0.67±0.09 ** 0.83±0.17 ▲ 0.77±0.13 ▲ 0.71±0.12 0.81±0.18 ▲ 1.03±0.15 ▲#※ |
Compare with normal group,
*P＜0.01; Compare with model group,
▲P＜0.05,
▲ ▲P＜0.01;
Compare with the Herb Gynostemmae Pentaphylli total glycosides group,
#Compare with the Fructus Crataegi total flavones group P＜0.05,
※P＜0.05
Embodiment 10 Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones share the atherosclerotic influence of rabbit
60 (body weight 2～2.5kg) of healthy male New Zealand large ear rabbit, the high lipid food (containing 96% normal feedstuff, 0.5% cholesterol, 3.5% Adeps Sus domestica, 0.05% cholate) of feeding, other gets 12 normal rabbits as the normal control group, the normal control group rabbit normal diet of feeding.After 4 weeks, change of serum C HO, TG, HDL, LDL are surveyed in blood sampling.According to blood lipid level (being mainly CHO, LDL) with rabbit by being divided into normal control group, model group, Herb Gynostemmae Pentaphylli total glycosides group (9mg/kg), Folium Crataegi total flavones group (18mg/kg), Herb Gynostemmae Pentaphylli total glycosides+Folium Crataegi total flavones group (4.5+9mg/kg), Herb Gynostemmae Pentaphylli total glycosides+Folium Crataegi total flavones group (9+18mg/kg) at random.Gastric infusion, every day 2 times, continuous 13 weeks, the 13rd fasting at weekend 12 hours, chloral hydrate anesthesia is got the hematometry serum lipids, serum endothelin (ET) and nitric oxide (NO) level; Gather the aorta sample, detect aorta lipid plaque area with image analytical method, light microscopic is observed the variation of aorta wall down.
The result: compare with normal group, model group rabbit anteserum TC, TG, LDL all significantly increase, and HDL significantly reduces.All can significantly reduce rabbit anteserum TC, TG, LDL with model group comparison Herb Gynostemmae Pentaphylli total glycosides, Folium Crataegi total flavones group, rising HDL, Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones share, the unusual effect of blood lipid regulation is better than Herb Gynostemmae Pentaphylli total glycosides or Folium Crataegi total flavones list group, shows that both share the abnormal change that can further improve arteriosclerosis rabbit blood fat.See Table 2.
Table 2 Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones to the influence of arteriosclerosis rabbit anteserum lipid (
N=9～11)
| Group | Dosage (mg/kg) | TC (mmol/L) | TG (mmol/L) | LDL (mmol/L) | HDL (mmol/L) |
| Total glycosides+the general flavone of the normal group model group total glycosides+general flavone of total glycosides general flavone | - - 9 18 4.5+9 9+18 | 1.56±0.42 13.71±3.43 ** 10.73±3.21 ▲ 9.62±4.01 ▲▲ 7.88±2.11 ▲▲# 7.09±1.55 ▲▲##※ | 1.01±0.35 3.47±1.42 ** 2.76±0.46 ▲ 2.19±0.54 ▲ 2.14±0.41 ▲▲## 1.79±0.33 ▲▲##※ | 0.46±0.36 12.12±4.10 **9.44±1.85 ▲8.86±2.18 ▲▲8.82±3.15 ▲▲7.32±2.14 ▲▲# | 1.16±0.34 0.65±0.19 **0.74±0.23 0.79±0.13 0.83±0.16 ▲▲0.98±0.13 ▲▲##※ |
Compare with normal group,
*P＜0.01; Compare with model group,
▲P＜0.05,
▲ ▲P＜0.01;
Compare with the Herb Gynostemmae Pentaphylli total glycosides group,
#P＜0.05,
##Compare with the Fructus Crataegi total flavones group P＜0.01,
※P＜0.05
Compare with normal group, the rabbit aorta MDA of model group man level significantly raises, and SOD content significantly reduces, and Folium Crataegi total flavones group, the rabbit aorta MDA of Herb Gynostemmae Pentaphylli total glycosides group man level obviously reduce, and SOD content raises, and has compared significant difference with model group; Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones share, and its effect is better than Herb Gynostemmae Pentaphylli total glycosides or Fructus Crataegi total flavones list with group, show that Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi total flavones share can significantly strengthen lipoid peroxidization resistant.See Table 3.
Compare model group rabbit anteserum No with normal group
2 -1Content significantly reduces, and blood plasma ET content obviously raises, and Herb Gynostemmae Pentaphylli total glycosides group and Fructus Crataegi total flavones group all can make No
2 -1Content raises, and ET content reduces; And Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi total flavones share, and its effect is better than Herb Gynostemmae Pentaphylli total glycosides or Fructus Crataegi total flavones list with group, show that Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi total flavones share can further regulate the NO/ET balance.The results are shown in Table 3.
Normal group aorta inner wall smooth is not seen lipid speckle, lipid striped and atheromatous plaque.Model group aortic arch to ventral aorta place has tangible atheromatous plaque.Speckle almost covers the whole piece aorta, especially aortic arch place speckle yellow skin and obviously protuberance.There is atheromatous plaque at Herb Gynostemmae Pentaphylli total glycosides group and Fructus Crataegi total flavones group aortic arch place, and the ventral aorta atheromatous plaque is few, and relatively the shared area coverage of speckle is little and speckle is thinner with model group.The rabbit aorta wall plaque area of Herb Gynostemmae Pentaphylli total glycosides+Fructus Crataegi total flavones group be lower than the Herb Gynostemmae Pentaphylli total glycosides group and with the Fructus Crataegi total flavones group.The results are shown in Table 4.
Table 3 Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones are to the rabbit aorta MDA of arteriosclerosis man, SOD, serum N o
2 -1, ET influence (
N=9～11)
| Group | Dosage (mg/kg) | MDA (μmol.g -1) | SOD (kU.g -1) | NO 2 -1Content (μ mol.L -1) | ET content (Pg.ml -1) |
| Total glycosides+the general flavone of the normal group model group total glycosides+general flavone of total glycosides general flavone | - - 9 18 4.5+9 9+18 | 1.52±0.45 3.14±0.89 **2.41±0.67 ▲2.34±0.49 ▲▲1.78±0.62 ▲▲#※1.84±0.37 ▲▲#※ | 76.3±10.2 48.4±8.7 **53.2±9.6 58.9±9.3 ▲69.2±7.4 ▲▲#※70.9±10.3 ▲▲##※ | 84.6±12.1 44.7±9.87 ** 56.8±13.2 ▲▲ 59.3±14.6 ▲▲ 65.2±12.7 ▲▲ 64.7±6.1 ▲▲# | 377.2±45.6 572.6±56.5 ** 529.4±111.5 534.7±68.7 487.4±89.1 ▲ 429.4±49.5 ▲▲#※ |
Compare with normal group,
*P＜0.01; Compare with model group,
▲P＜0.05,
▲ ▲P＜0.01;
Compare with the Herb Gynostemmae Pentaphylli total glycosides group,
#Compare with the Fructus Crataegi total flavones group P＜0.05,
※P＜0.05
Table 4 Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones to the influence of arteriosclerosis rabbit atherosclerosis of aorta plaque area, inner film thickness, media thickness and inner membrance foam cell number (
N=9～11)
| Group | Dosage (mg/kg) | Aorta wall plaque area (%) | Inner film thickness mm | Media thickness mm | Foam cell number/mm 2 |
| Total glycosides+the general flavone of the normal group model group total glycosides+general flavone of total glycosides general flavone | - - 9 18 4.5+9 9+18 | 0.0±0.0 45.4±6.1 **40.4±8.6 38.9±6.5 ▲35.3±7.9 ▲▲30.8±5.7 ▲▲#※ | 0.10±0.10 0.39±0.18 ** 0.27±0.08 ▲ 0.27±0.13 ▲ 0.25±0.12 ▲▲ 0.20±0.07 ▲▲# | 0.30±0.08 0.45±0.04 ** 0.41±0.10 0.34±0.07 ▲▲ 0.35±0.06 ▲▲ 0.30±0.09 ▲▲# | 3.4±1.6 24.4±5.6 ** 18.3±3.5 ▲▲ 20.6±3.7 ▲ 19.6±4.6 ▲▲ 16.6±3.4 ▲▲※ |
Compare with normal group,
*P＜0.01; Compare with model group,
▲P＜0.05,
▲ ▲P＜0.01;
Compare with the Herb Gynostemmae Pentaphylli total glycosides group,
#Compare with the Fructus Crataegi total flavones group P＜0.05,
※P＜0.05
Om observation: the normal group endotheliocyte is flat, and inner membrance is smooth, and the middle level smooth muscle cell is approximate parallel alternately with elastic plate; The visible a large amount of foam cells of model group arterial wall, being mosaic arranges, endothelial denudation, elastic plate thickens and ruptures, middle rete smooth muscle fracture, arrangement disorder, each administration group all has in various degree the intimal thickening based on SMC, the elastic plate became uneven has the fracture segregation phenomenon, middle slight hypertrophy of film shallow-layer SMC and arrangement disorder.
Model group aortic tunica intima hypertrophy, foam cell quantity increases, and compares with model group, and each administration group all can reduce media thickness, and obvious with Herb Gynostemmae Pentaphylli total glycosides+Fructus Crataegi total flavones group, is better than each single medicine group.See Table 4.
In sum, Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi total flavones share, and can work in coordination with blood lipid regulation, protect endotheliocyte, anti peroxidation of lipid, delay target organ damage, reduce atheromatous plaque and form, comprehensively the control of cardiovascular disorders risk factor.
Embodiment 11 Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi extract (total flavones) are to the preventive and therapeutic effect of rat fat liver
119 of male SD rats, adaptability was fed after 7 days, be divided into normal group, model group, Herb Gynostemmae Pentaphylli total glycosides group (18mg/kg), Fructus Crataegi extract (total flavones) group (18mg/kg), Herb Gynostemmae Pentaphylli total glycosides+Fructus Crataegi extract (total flavones) low dose group (4.5+4.5mg/kg), middle dosage group (9+9mg/kg), high dose group (18+18mg/kg), 17 every group.Normal control group feed normal diet, all the other rats are fed, and (prescription is high lipid food: 84% normal feedstuff+10% Adeps Sus domestica+5% yolk powder+1% cholesterol), and in the 1st day lumbar injection tetracycline 150mg/kg of modeling, tetracycline 100mg/kg of per thereafter 6 days lumbar injections counts 6 times.The modeling while, gastric infusion, normal control group and model group give equivalent 0.5%CMC-Na solution, every day 2 times, continuous 8 weeks, measure liver lipid (TC, TG) the 8th weekend, liver function (ALT, AST), and carry out pathological examination.
Result: compare with normal group, model group rat liver TC, TG, ALT, AST level significantly raise, serious steatosis appears in part of hepatocytes, extremely swelling is rounded for hepatocyte, as seen the fat that differ in size in the endochylema, quantity differs drips cavity (steatosis), shows rat fat liver modelling success.Herb Gynostemmae Pentaphylli total glycosides, Fructus Crataegi total flavones group rat liver TC, TG, ALT, AST significantly reduce, and with model group significant difference are arranged relatively; Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi total flavones share, and its effect is better than Herb Gynostemmae Pentaphylli total glycosides or Fructus Crataegi total flavones list group, and certain dose-effect relationship is arranged between high, medium and low dosage.Showing that Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi total flavones share can further improve liver lipid metabolic disorder, liver function protecting.See Table 5.
Perusal: normal rats liver profile is normal, kermesinus, and tunicle is smooth.Model group rat liver volume obviously increases, and weight increases, the peplos anxiety, and the edge rust, mattness is lark, the quality deliquescing, tangent plane is lark, and obvious greasy feeling is arranged.Each administration group pathologic changes and alleviates, wherein liver volume dwindle, weight saving, surperficial light red, quality is softer, the tangent plane greasy feeling is not obvious, Herb Gynostemmae Pentaphylli total glycosides+Fructus Crataegi total flavones group is better than single medicine group.
Light microscopic is observed down: normal rats hepatic tissue structural integrity, clear, and the lobules of liver structure is normal, and the hepatocyte queueing discipline becomes strand, becomes radial distribution around central vein.The hepatic sinusoid clear in structure, no abnormal change.Hepatocyte is polygon, and endochylema is even, inclined to one side acidophilia, and karyomorphism is normal.Model group rats'liver lobule boundary is unclear, the hepatic cords arrangement disorder, most of sinus hepaticus disappears, serious steatosis appears in part of hepatocytes, and is the most serious with the lobule periphery, and extremely swelling is rounded for hepatocyte, as seen the fat that differ in size in the endochylema, quantity differs drips cavity (steatosis), severe patient fat drips mutual fusion, and nucleus is extruded into cell one side, exactly likes adipose cell.Part of hepatocytes is also shown in focal necrosis, and matter does not have the obvious fibrosis change between liver.Herb Gynostemmae Pentaphylli total glycosides+Fructus Crataegi total flavones group rats'liver lobule and hepatic sinusoid clear in structure, the cell marshalling, visible little fat drips cavity in a small amount of hepatocyte, and the karyomorphism structure is normal, can see regenerated hepatocyte.With model group relatively, each medication group rat hepatocytes steatosis degree all has significantly and alleviates, but Herb Gynostemmae Pentaphylli total glycosides+Fructus Crataegi total flavones group is better than single medicine group.Computer image analysis is made in 3 visuals field of every section random observation under light microscopic, calculates fat and becomes the percentage rate that hepatic tissue accounts for the visual field gross area, the results are shown in Table 6.
Table 5 Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi extract (total flavones) are to fatty liver rat liver TC, TG and transaminase's influence
| Group | Dosage (mg/kg) | Number of animals | TC (μmol/g) | TG (μmol/g) | ALT (U/L -1) | AST (U/L -1) |
| Normal group model group total glycosides total flavones total glycosides+total flavones | - - 18 18 4.5+4.5 9+9 18+18 | 15 13 15 13 14 14 15 | 96±18 288±84 ** 215±59 ▲ 203±47 ▲ 230±72 160±32 ▲▲※ 136±29 ▲▲##※※ | 67±20 195±42 **152±32 ▲138±34 ▲▲160±30 ▲125±30 ▲▲#112±42 ▲▲# | 8.2±2.3 63.4±8.5 **45±8.9 ▲▲55±6.7 ▲▲50±7.2 ▲▲45±6.7 ▲▲48±6.2 ▲▲ | 38.2±10.2 102.6±24.2 ** 70.1±16.9 ▲▲ 79.7±20.4 ▲ 84.1±10.8 ▲▲ 58.2±7.9 ▲▲※ 49.7±10.9 ▲#※ |
Compare with normal group,
*P＜0.01; Compare with model group,
▲P＜0.05,
▲ ▲P＜0.01; Compare with the Herb Gynostemmae Pentaphylli total glycosides group,
#P＜0.05,
##Compare with the Fructus Crataegi total flavones group P＜0.01,
※P＜0.05,
※ ※P＜0.01
Table 6 Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones are organized percentile influence to fatty liver rat liver index, liver cell fatty degeneration
| Group | Dosage (mg/kg) | Number of animals | Liver index (%) | Liver cell fatty degeneration (%) |
| Normal group model group total glycosides total flavones total glycosides+total flavones | - - 18 18 4.5+4.5 9+9 18+18 | 15 13 15 13 14 14 15 | 3.12±0.23 4.11±0.35 ** 3.6±0.55 ▲ 3.7±0.29 ▲ 3.8±0.26 ▲ 3.3±0.28 ▲▲※ 3.4±0.29 ▲▲※ | 0±0 24.4±4.5 ** 20.4±4.9 ▲ 18.1±3.8 ▲▲ 22.5±4.7 18.3±3.2 ▲▲ 15.4±5.0 ▲▲# |
Compare with normal group,
*P＜0.01; Compare with model group,
▲P＜0.05,
▲ ▲P＜0.01;
Compare with the Herb Gynostemmae Pentaphylli total glycosides group,
#P＜0.05,
##Compare with the Fructus Crataegi total flavones group P＜0.01,
※P＜0.05,
※ ※P＜0.01
Embodiment 12 Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi extract (total flavones) are to the preventive and therapeutic effect of rat metabolism syndrome
150 of male Wistar rats, adaptability was fed after 7 days, got 15 and was normal control group, feed normal diet; All the other rats are on the feed under the condition, press 15mg/kg lumbar injection streptozotocin (STZ), the 2nd day injection CFA 0.5ml/kg, 1 time weekly, continuous 3 weeks, the high lipid food of feeding simultaneously (prescription is: Adeps Sus domestica 20%, white sugar 10%, defatted milk powder 10%, cholesterol 2%, cholate 0.5%, edible salt 5%, normal feedstuff 53.5%).The 4th weekend, after the fasting 12 hours, get hematometry rat blood sugar, serum TC, TG, divide into groups according to situations such as rat body weight, blood glucose, serum TC, TG, be respectively model group, Herb Gynostemmae Pentaphylli total glycosides group (18mg/kg), Fructus Crataegi extract (total flavones) group (18mg/kg), Herb Gynostemmae Pentaphylli total glycosides+Fructus Crataegi extract (total flavones) low dose group (9+9mg/kg), middle dosage group (18+18mg/kg), high dose group (36+36mg/kg), 15 every group.Gastric infusion, every day 2 times, normal control group and model group give equivalent 0.5%CMC-Na solution, continuous 20 weeks, measure rat body weight weekly, measure rat blood pressure per 4 weeks, blood glucose, collect urine the 20th weekend, survey 24h urine creatine (Scr), urine protein, 24h and urinate α
1Microglobulin (α 1-MG); Get the hematometry serum creatinine, serum calculates creatinine clearance rate (Ccr).Measure rat fasting blood-glucose (FBG), fasting insulin (FINS), blood fat, execution is got around mesentery, the bilateral kidney and the other fat of epididymis is weighed, and calculates fat coefficient.
The result: compare with normal group, weight increase, hypertension, interior fat increase, blood fat rising, blood glucose, insulin level rising appear in the model group rat, and insulin resistant occurs, show that typical metabolism syndrome performance appears in rat.Herb Gynostemmae Pentaphylli total glycosides, Fructus Crataegi extract (total flavones) group rat body weight reduce, blood pressure reduces, interior fat reduces, and insulin sensitivity index (ISI) increases, and serum TG, TC, LDL reduce, and have compared significant difference with model group.Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi extract (total flavones) share, and rat body weight, interior fat, fasting glucose, fasting insulin, blood fat further reduce, and ISI increases, and compares with single medicine group, and significant difference is arranged.Show that Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi extract (total flavones) share, can significantly work in coordination with control rat metabolism syndrome, increase the sensitivity of body insulin.See Table 7～9.
Table 7 Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi extract (total flavones) to the influence of metabolism syndrome rat body weight, blood pressure, interior fat (
N=10～13)
| Group | Dosage (mg/kg) | Body weight (g) | Blood pressure (mmHg) | Interior fat (g) | Fat coefficient (g/100g body weight) |
| Normal group model group total glycosides total flavones total glycosides+total flavones | - - 18 18 9+9 18+18 36+36 | 389±32 487±43 **443±26 ▲▲432±31 ▲▲412±29 ▲▲※402±31 ▲▲#※372±37 ▲▲##※※ | 118±13 147±14 ** 136±16 133±8 ▲▲ 123±15 ▲▲ 124±11 ▲▲# 129±13 ▲▲ | 10.5±3.2 30.6±5.7 ** 20.9±3.3 ▲▲ 21.2±2.9 ▲▲ 17.2±3.8 ▲▲#※ 15.4±4.1 ▲▲ 15.3±3.4 ▲▲##※ | 2.74±1.10 6.38±1.71 ** 4.61±1.29 ▲▲ 4.93±1.25 ▲▲ 4.03±0.84 ▲▲ 3.65±1.11 ▲▲#※ 3.98±0.93 ▲▲#※ |
Compare with normal group,
*P＜0.01; Compare with model group,
▲P＜0.05,
▲ ▲P＜0.01;
Compare with the Herb Gynostemmae Pentaphylli total glycosides group,
#P＜0.05,
##Compare with the Fructus Crataegi total flavones group P＜0.01,
※P＜0.05,
※ ※P＜0.01
Compare with normal group, model group rat urine protein, α 1-MG significantly raise, and blood Ccr significantly reduces, and shows that renal function injury appears in the metabolism syndrome rat.Compare with model group, Herb Gynostemmae Pentaphylli total glycosides, Fructus Crataegi extract (total flavones) group rat urine α 1-MG, urine protein reduce, and blood Ccr raises.Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi extract (total flavones) share; rat urine protein, α 1-MG further reduce; and blood Ccr further raises; there were significant differences to organize comparison with Herb Gynostemmae Pentaphylli total glycosides or Fructus Crataegi extract (total flavones), shows that Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi extract (total flavones) share the protective effect that can significantly strengthen metabolism syndrome kidney of rats function.See Table 10.
Table 8 Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi extract (total flavones) to the influence of metabolism syndrome rat fasting blood-glucose, fasting insulin, insulin sensitivity index (
N=10～13)
| Group | Dosage (mg/kg) | Fasting blood sugar (mmol/L) | Insulin content (mIU/L) | ISI |
| Normal group model group total glycosides total flavones total glycosides+total flavones | - - 18 18 9+9 18+18 36+36 | 5.17±1.15 15.44±3.29 ** 12.46±3.32 13.74±3.48 12.25±3.14 ▲ 11.66±2.83 ▲▲ 11.25±2.95 ▲▲ | 22.05±4.01 31.47±5.85 ** 26.09±6.30 26.87±6.95 24.13±5.54 21.39±5.14 ▲▲ 21.51±4.11 ▲▲ | -4.70±0.24 -6.15±0.25 ** -5.72±0.33 ▲▲ -5.85±0.32 ▲ -5.63±0.18 ▲▲※ -5.46±0.20 ▲▲#※ -5.44±0.27 ▲▲#※ |
Compare with normal group,
*P＜0.01; Compare with model group,
▲P＜0.05,
▲ ▲P＜0.01;
Compare with the Herb Gynostemmae Pentaphylli total glycosides group,
#P＜0.05,
##Compare with the Fructus Crataegi total flavones group P＜0.01,
※P＜0.05,
※ ※P＜0.01
Table 9 Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi extract (total flavones) to the influence of metabolism syndrome rat fat (
N=10～13)
| Group | Dosage (mg/kg) | TC (mmol/L) | TG (mmol/L) | LDL-C (mmol/L) | HDL-C (mmol/L) |
| Normal group model group total glycosides total flavones total glycosides+total flavones | - - 18 18 9+9 18+18 36+36 | 1.41±0.35 15.72±3.45 ** 12.05±3.39 ▲ 13.13±2.56 ▲ 10.23±3.32 ▲▲※ 8.13±2.56 ▲▲#※ 9.41±1.35 ▲▲#※ | 1.26±0.32 2.83±0.49 **2.45±0.32 ▲2.39±0.34 ▲1.92±0.25 ▲▲##※※1.59±0.34 ▲▲##※※1.76±0.42 ▲▲##※※ | 0.67±0.14 14.54±2.42 **11.02±1.87 ▲12.05±1.79 9.57±2.62 ▲▲#※8.05±1.79 ▲▲#※8.67±2.14 ▲▲#※ | 1.21±0.15 0.47±0.18 * 0.72±0.26 0.70±0.15 0.78±0.24 0.83±0.25 0.86±0.23 |
Compare with normal group,
*P＜0.01; Compare with model group,
▲P＜0.05,
▲ ▲P＜0.01;
Compare with the Herb Gynostemmae Pentaphylli total glycosides group,
#P＜0.05,
##Compare with the Fructus Crataegi total flavones group P＜0.01,
※P＜0.05,
※ ※P＜0.01
Table 10 Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi extract (total flavones) are to metabolism syndrome rat α
1The influence of-microglobulin, urine protein, creatinine clearance rate (
N=10～13)
| Group | Dosage (mg/kg) | 24hα 1-microglobulin (μ g) | Urine protein (mg) | Ccr (ml/min) |
| Normal group model group total glycosides total flavones total glycosides+total flavones | - - 18 18 9+9 18+18 36+36 | 19.4±6.8 83.2±20.9 **64.1±17.4 ▲▲66.0±15.0 ▲50.3±12.3 ▲▲#※55.1±16.4 ▲▲46.2±12.4 ▲▲#※ | 17.3±5.8 55.2±16.7 ** 45.2±14.9 ▲▲ 42.6±10.9 ▲▲ 29.0±6.9 ▲▲#※ 25.1±8.2 ▲▲#※ 26.8±7.4 ▲▲#※ | 4.14±1.23 2.78±0.45 ** 3.21±0.40 ** 3.16±0.45 ▲▲ 3.56±0.48 ▲▲ 3.88±0.62 ▲▲#※ 3.91±0.65 ▲▲#※ |
Compare with normal group,
*P＜0.01; Compare with model group,
▲P＜0.05,
▲ ▲P＜0.01;
Compare with the Herb Gynostemmae Pentaphylli total glycosides group,
#P＜0.05,
##Compare with the Fructus Crataegi total flavones group P＜0.01,
※P＜0.05,
※ ※P＜0.01
Embodiment 13 Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones share the preventive and therapeutic effect to the rat fat liver
Male SD rat is divided into normal group, model group, Herb Gynostemmae Pentaphylli total glycosides group (36mg/kg), Folium Crataegi total flavones group (9mg/kg), Herb Gynostemmae Pentaphylli total glycosides+Folium Crataegi total flavones group (18+4.5mg/kg), Herb Gynostemmae Pentaphylli total glycosides+Folium Crataegi total flavones group (36+9mg/kg), 14 every group.Normal control group feed normal diet, all the other rats are fed, and (prescription is high lipid food: 84% normal feedstuff+10% Adeps Sus domestica+5% yolk powder+1% cholesterol), and in the 1st day lumbar injection tetracycline 150mg/kg of modeling, tetracycline 100mg/kg of per thereafter 6 days lumbar injections.The modeling while, gastric infusion, normal control group and model group give equivalent 0.5%CMC-Na solution, every day 2 times, continuous 8 weeks, measure the liver lipid the 8th weekend, liver function, and carry out pathological examination.The result shows that Herb Gynostemmae Pentaphylli total glycosides, Folium Crataegi total flavones group rat liver TC, TG, ALT, AST significantly reduce than model group; Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones share, and its effect is better than Herb Gynostemmae Pentaphylli total glycosides or Folium Crataegi total flavones list with group, show that Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones share to work in coordination with to improve liver lipid metabolic disorder, liver function protecting.Light microscopic is observed down, and the more single medicine group of rat hepatocytes steatosis degree of Herb Gynostemmae Pentaphylli total glycosides+Folium Crataegi total flavones group has significantly and alleviates.
Embodiment 14 Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones share the preventive and therapeutic effect to the rat metabolism syndrome
With male Wistar rat, get 12 and be normal control group, feed normal diet; All the other rats are on the feed under the condition, press 15mg/kg lumbar injection streptozotocin (STZ), the 2nd day injection CFA 0.5ml/kg, 1 time weekly, continuous 3 weeks, the high lipid food of feeding simultaneously (prescription is: Adeps Sus domestica 20%, white sugar 10%, defatted milk powder 10%, cholesterol 2%, cholate 0.5%, edible salt 5%, normal feedstuff 53.5%).The 4th weekend, after the fasting 12 hours, get hematometry rat blood sugar, serum TC, TG, divide into groups according to situations such as rat body weight, blood glucose, serum TC, TG, be respectively model group, Herb Gynostemmae Pentaphylli total glycosides group (9mg/kg), Folium Crataegi total flavones group (36mg/kg), Herb Gynostemmae Pentaphylli total glycosides+Folium Crataegi total flavones group (4.5+18mg/kg), Herb Gynostemmae Pentaphylli total glycosides+Folium Crataegi total flavones group (9+36mg/kg), 12 every group.Gastric infusion, every day 2 times, normal control group and model group give equivalent 0.5%CMC-Na solution, continuous 20 weeks, measure rat body weight weekly, measure rat blood pressure per 4 weeks, blood glucose, measure rat fasting blood-glucose (FBG), fasting insulin (FINS), blood fat the 20th weekend, execution is got around mesentery, the bilateral kidney and the other fat of epididymis is weighed, and calculates fat coefficient.The result shows that Herb Gynostemmae Pentaphylli total glycosides, the reduction of Folium Crataegi total flavones group rat body weight, blood pressure reduction, serum TG, TC, LDL reduce, and interior fat reduces, and insulin sensitivity index (ISI) increases, and than model group difference statistical significance is arranged.Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones share, and rat body weight, blood fat, interior fat, fasting glucose, fasting insulin further reduce, and ISI increases, and compares with single medicine group, and difference has statistical significance.Show that Herb Gynostemmae Pentaphylli total glycosides and Folium Crataegi total flavones share, can significantly work in coordination with control rat metabolism syndrome, increase the sensitivity of body insulin.
Embodiment 15 Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi extract (total flavones) share the influence to the hyperlipemia rat blood fat
120 of male SD rats, adaptability was fed after 7 days, and the high lipid food of feeding (prescription is: 7.5% Adeps Sus domestica, 0.8% cholesterol, 0.2% sodium cholate, 0.1% propylthiouracil, normal feedstuff 91.4%) is drunk 2% sucrose solution simultaneously.Other gets 15 and is the normal control group, the feed normal diet, and the 4th weekend, fasting was got hematometry Serum TC, TG after 12 hours, and the rat that serum TC, TG all significantly raise is a hyperlipidemia rats.
Hyperlipidemia rats is divided into model group, Herb Gynostemmae Pentaphylli total glycosides group (18mg/kg), Fructus Crataegi extract (total flavones) group (9mg/kg), Herb Gynostemmae Pentaphylli total glycosides+Fructus Crataegi extract (total flavones) low dose group (9+4.5mg/kg), middle dosage group (18+9mg/kg), high dose group (36+18mg/kg), 15 every group at random.Continue the high lipid food of feeding, gastric infusion, normal control group and model group give equivalent 0.5%CMC-Na solution, every day 2 times, in continuous 8 weeks, measure serum TC, TG, LDL, HDL the 8th weekend.
The result: compare with normal group, model group Serum TC, TG, LDL level significantly raise, and the HDL level reduces.Herb Gynostemmae Pentaphylli total glycosides group, Fructus Crataegi extract (total flavones) group Serum TC, TG, LDL obviously reduce, and the HDL level raises, and has compared significant difference with model group; Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi extract (total flavones) share, Serum TC, TG, LDL further reduce, the HDL level further raises, wherein middle dosage group effect is better than Herb Gynostemmae Pentaphylli total glycosides or Fructus Crataegi extract (total flavones) is single with group, and has certain dose-effect relationship between the high, medium and low dosage group.
Show: the high lipid food of feeding can successfully duplicate the rat high blood lipid model, Herb Gynostemmae Pentaphylli total glycosides, Fructus Crataegi extract (total flavones) gastric infusion, significantly improve the hyperlipidemia rats dyslipidemia, Herb Gynostemmae Pentaphylli total glycosides and Fructus Crataegi extract (total flavones) share has significant synergism to blood lipid regulation.
Embodiment 16 preparation Folium Crataegi total flavones Herb Gynostemmae Pentaphylli total glycosides slow releasing tablet
Take by weighing Folium Crataegi total flavones 90g, Herb Gynostemmae Pentaphylli total glycosides 180g, polyvinyl pyrrolidone K
9035g and 243g hydroxypropyl emthylcellulose, mix homogeneously as mixed powder, is used 50% alcohol granulation, and drying behind the granulate, adds magnesium stearate 10g and hydroxypropyl emthylcellulose 42g, and mix homogeneously is pressed into 1000, promptly.Every of this product contains hyperin (C
21H
20O
12), must not be less than 0.12mg, contain total glycosides with gypenoside-A (C
53H
90O
21) meter, should be 90～110% of labelled amount.
Embodiment 17 preparation Fructus Crataegi extract Herb Gynostemmae Pentaphylli total glycosides slow releasing tablet
Take by weighing Fructus Crataegi extract 180g, Herb Gynostemmae Pentaphylli total glycosides 180g, polyvinyl pyrrolidone K90 45g and 239g hydroxypropyl emthylcellulose, mix homogeneously, as mixed powder, use 50% alcohol granulation, drying is behind the granulate, add magnesium stearate 13g and hydroxypropyl emthylcellulose 43g, mix homogeneously is pressed into 1000, promptly.This product contains total flavones with anhydrous Quercetin (C
15H
10O
7) calculate, every must not be less than 13.5mg, contains total glycosides with gypenoside-A (C
53H
90O
21) meter, should be 90～110% of labelled amount.
Claims (11)
1. a Chinese medicine compound is characterized in that, is made by the Chinese medicine extract of following weight proportion: Fructus Crataegi total flavones, Herb Gynostemmae Pentaphylli total glycosides, and pharmaceutics on acceptable carrier an amount of; Wherein the weight proportion of Fructus Crataegi total flavones and Herb Gynostemmae Pentaphylli total glycosides is 1: 4～4: 1; Fructus Crataegi total flavones is total flavones that extracts or the total flavones that extracts from Folium Crataegi from Fructus Crataegi.
2. the Chinese medicine compound of claim 1 is characterized in that, preferred 1: 2～2: 1 of the weight proportion of Fructus Crataegi total flavones and Herb Gynostemmae Pentaphylli total glycosides.
3. the Chinese medicine compound of claim 2 is characterized in that, the weight proportion of Fructus Crataegi total flavones and Herb Gynostemmae Pentaphylli total glycosides is more preferably 1: 1.
4. the Chinese medicine compound of claim 1 is characterized in that, described Fructus Crataegi total flavones 30～120mg, Herb Gynostemmae Pentaphylli total glycosides 120～30mg.
5. the Chinese medicine compound of claim 4 is characterized in that, described Fructus Crataegi total flavones 30～60mg, Herb Gynostemmae Pentaphylli total glycosides 60～30mg.
6. the Chinese medicine compound of claim 5 is characterized in that, described Fructus Crataegi total flavones 60mg, Herb Gynostemmae Pentaphylli total glycosides 60mg.
7. arbitrary described Chinese medicine compound in the claim 1～6 is characterized in that its pharmacy dosage form is oral liquid, tablet, capsule, soft capsule, granule, buccal tablet, electuary, pellet, pill, sustained-release micro-spheres agent, powder, suspensoid, powder, drop or solution.
8. the application of arbitrary described Chinese medicine compound in the medicine of preparation control metabolism syndrome in the claim 1～6.
9. the application of arbitrary described Chinese medicine compound in the medicine of the anti-curing hyperlipemia of preparation in the claim 1～6.
10. arbitrary described Chinese medicine compound is prevented and treated application in the medicine of atherosclerosis or coronary heart disease in preparation in the claim 1～6.
11. the application of arbitrary described Chinese medicine compound in the lipotropic medicine of preparation in the claim 1～6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100800680A CN101069710A (en) | 2006-05-11 | 2006-05-11 | Compounded medicine for preventing and treating metabolic syndrome and hyperlimemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100800680A CN101069710A (en) | 2006-05-11 | 2006-05-11 | Compounded medicine for preventing and treating metabolic syndrome and hyperlimemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101069710A true CN101069710A (en) | 2007-11-14 |
Family
ID=38897228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006100800680A Pending CN101069710A (en) | 2006-05-11 | 2006-05-11 | Compounded medicine for preventing and treating metabolic syndrome and hyperlimemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101069710A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919985A (en) * | 2009-06-10 | 2010-12-22 | 南方医科大学南方医院 | Drug for treating fatty liver and preparation method and use thereof |
| CN102526263A (en) * | 2011-12-20 | 2012-07-04 | 瑞坝（北京）新能源科技有限公司 | Plant health care product for preventing and treating gout |
| CN102579628A (en) * | 2012-03-09 | 2012-07-18 | 施慧达药业集团(吉林)有限公司 | Chinese medicinal preparation for treating hyperlipidaemia and preparation method thereof |
| CN104606275A (en) * | 2014-04-10 | 2015-05-13 | 宁波市第二医院 | Traditional Chinese medicine effective component compound for preventing and treating fatty liver |
| CN109329689A (en) * | 2018-11-12 | 2019-02-15 | 天津市农业生物技术研究中心 | A kind of health solid beverage and preparation method thereof |
| CN115300552A (en) * | 2022-02-11 | 2022-11-08 | 浙江中医药大学 | Application of hawthorn total flavonoids in preparation of medicine for preventing or treating metabolic syndrome |
-
2006
- 2006-05-11 CN CNA2006100800680A patent/CN101069710A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919985A (en) * | 2009-06-10 | 2010-12-22 | 南方医科大学南方医院 | Drug for treating fatty liver and preparation method and use thereof |
| CN102526263A (en) * | 2011-12-20 | 2012-07-04 | 瑞坝（北京）新能源科技有限公司 | Plant health care product for preventing and treating gout |
| CN102579628A (en) * | 2012-03-09 | 2012-07-18 | 施慧达药业集团(吉林)有限公司 | Chinese medicinal preparation for treating hyperlipidaemia and preparation method thereof |
| CN104606275A (en) * | 2014-04-10 | 2015-05-13 | 宁波市第二医院 | Traditional Chinese medicine effective component compound for preventing and treating fatty liver |
| CN109329689A (en) * | 2018-11-12 | 2019-02-15 | 天津市农业生物技术研究中心 | A kind of health solid beverage and preparation method thereof |
| CN115300552A (en) * | 2022-02-11 | 2022-11-08 | 浙江中医药大学 | Application of hawthorn total flavonoids in preparation of medicine for preventing or treating metabolic syndrome |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN101069710A (en) | Compounded medicine for preventing and treating metabolic syndrome and hyperlimemia | |
| CN101181373B (en) | Cortex moutan valid target pharmaceutical combination, preparation method and application thereof | |
| CN100509016C (en) | Hyperlipemia treating medicine and preparation method thereof | |
| CN101199668B (en) | Chinese medicine agent for treating alcohol fatty liver and preparing method thereof | |
| CN100493572C (en) | Composition of medication for treating diabetes | |
| CN102008598B (en) | Blood fat-lowering and liver-protecting composite as well as preparation prepared thereby and preparation method of preparation | |
| CN111110735A (en) | Lipid-lowering pharmaceutical composition, preparation method and application | |
| CN111195310A (en) | Traditional Chinese medicine composition for treating hyperlipidemia | |
| CN104721467A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and application thereof | |
| CN100382807C (en) | Natural medicine composition for preventing and treating metabolic syndrome | |
| CN101590095B (en) | Compound medicine containing gypenosides and folic acid compound | |
| CN109157584B (en) | Composition with auxiliary blood fat reducing function and preparation method and application thereof | |
| WO2022021638A1 (en) | Traditional chinese medicinal composition for invigorating spleen and removing turbidity and application thereof | |
| CN101590127B (en) | Compound medicine containing total flavone of hawthorn (leaf) and folic acid compound | |
| CN103860877B (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN111603506A (en) | Application of stomach-regulating qi-supporting decoction in preparation of medicine for preventing and treating metabolic syndrome caused by olanzapine taken by schizophrenia patient | |
| CN105816549B (en) | A kind of drug and preparation method thereof for preventing and treating atherosclerotic plaque | |
| CN100355440C (en) | Compound Chinese medicinal preparation for treating type II diabetes and lowering blood sugar and its preparation method | |
| CN101112432A (en) | Fatty liver treating Chinese medicine and method for preparing the same | |
| CN102793798A (en) | Medicinal composition for auxiliary treatment of diabetic coronary artery disease | |
| CN102600382B (en) | Traditional Chinese compound preparation for strengthening spleen and soothing liver as well as application thereof | |
| CN101396457B (en) | Traditional Chinese medicine composition for treating stomach intestine adynamia of multi viscera organs incompetence syndrome | |
| CN108498761B (en) | Food, health-care product or pharmaceutical composition for treating yang jaundice and preparation method and application thereof | |
| CN102861186B (en) | Medicine for improving bioavailability of atorvastatin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20071114 |